European Journal of Clinical Pharmacology

, Volume 21, Issue 4, pp 335–341 | Cite as

Pharmacokinetics of3H-phenylephrine in man

  • J. H. Hengstmann
  • J. Goronzy


7-3H-phenylephrine was given to 15 volunteers by a short-infusionn=4) or p.o. (10 volunteers, 1 patient with porto-caval anastomosis). Analysis of serum for free3H-phenylephrine and fractionation of urinary radioactivity was performed by ion-exchange and thin-layer chromatography. As almost the same3H-activity was excreted in urine after i.v. and p.o. administration, 86% and 80% of the dose respectively, complete enteral absorption can be assumed. A considerable difference was seen in the fraction of free phenylephrine, i.v. 16% of the dose versus p.o. 2.6%, which suggested reduced bioavailability. This was confirmed by comparison of the areas under the serum curve, which showed a bioavailability factor of 0.38. The result for the patient with porto-caval anastomosis was comparable to that in the normal volunteers. The biological half-life of 2 to 3h was comparable to that of structurally related amines, as were the total clearance of 2 1/h, and the volume of distribution of 340l. Metabolism to phenolic conjugates mainly after oral ingestion, and tom-hydroxymandelic acid after i.v. injection, again demonstrated thatm-hydroxylated amines are predominantly conjugated during the “first-pass” metabolism.

Key words

phenylephrine pharmacokinetics bioavailability first-pass metabolism phenolic conjugates m-hydroxymandelic acid intravenous oral 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahlquist RP, Levy B (1959) Adrenergic receptive mechanism of canine ileum. J Pharmacol Exp Ther 127: 146–149Google Scholar
  2. Barger G, Dale HH (1910) Chemical structure and sympathomimetic action of amines. J Physiol (Lond) 41: 19–59Google Scholar
  3. Besarab A, Silva P, Landsberg L, Epstein F (1977) Effect of catecholamines on tubular function in the isolated perfused rat. Am J Physiol 233: F39-F45Google Scholar
  4. Borromeo-McGrail V, Bordiuk JM, Keitel H (1973) Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. Pediatrics 51: 1032–1036Google Scholar
  5. Bruce RB, Pitts JE (1968) The determination and excretion of phenylephrine in urine. Biochem Pharmacol 17: 335–337Google Scholar
  6. Dost FH (1968) Grundlagen der Pharmakokinetik. Thieme Verlag, StuttgartGoogle Scholar
  7. Elis J, Laurence DR, Mattie H, Prichard BNC (1967) Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J 2: 75–78Google Scholar
  8. Fraunfelder FT, Scafidi AF (1978) Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol 85: 447–453Google Scholar
  9. Govier WC (1967) A positive inotropic effect of phenylephrine mediated through alpha adrenergic receptors. Life Sci 6: 1361–1365Google Scholar
  10. Hengstmann JH (1976) Metabolic pattern and pharmacokinetic properties of phenolic sympathomimetic amines. Arzneim-Forsch (Drug Res) 26: 1254–1255Google Scholar
  11. Hengstmann JH, Aulepp H (1978) Pharmakokinetik und Metabolismus von3H-Synephrin. Arzneim-Forsch (Drug Res) 28: 2326–2331Google Scholar
  12. Hengstmann JH, Goronzy J (1980) Enterale Resorption und Bioverfügbarkeit von Norfenefrin. Arzneim-Forsch. (Drug Res) 30: 2164–2167Google Scholar
  13. Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJ (1974) The physiological disposition ofp-octopamine in man. Naunyn-Schmiedebergs Arch Pharmacol 283: 93–106Google Scholar
  14. Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJ (1975a) Bioavailability ofm-octopamine in man related to its metabolism. Eur J Clin Pharmacol 8: 33–39Google Scholar
  15. Hengstmann JH, Weyand U, Dengler HJ (1975b) The physiological disposition of etilefrine in man. Eur J Clin Pharmacol 9: 179–187Google Scholar
  16. Horvath SM, Knapp DW (1954) Hemodynamic effects of neosynephrine. Am J Physiol 178: 387–391Google Scholar
  17. Innes IR, Nickerson M (1975) Norepinephrine, epinephrine and the sympathomimetic amines. In: Gilman A, Goodman LS (eds) The pharmacological basis of therapeutics. 5th ed. Macmillan, New York, pp 477–513Google Scholar
  18. Kuschinsky G, Oberdisse K (1931) Die Kreislaufwirkungen des Meta-Sympatols. Arch Exper Pathol Pharmakol 162: 46–55Google Scholar
  19. Leong LSK, Benfey BG (1968) Actions of phenylephrine on contractility and rate of rabbit atria. Pharmacologist 10: 206Google Scholar
  20. Martinez TT, McNeill JH (1977) Cyclic AMP and the positive inotropic effect of norepinephrine and phenylephrine. Can J Physiol Pharmacol 279–287Google Scholar
  21. Quebbemann AJ, Rennick BR (1968) Catechol transport by the renale tubule in the chicken. Am J Physiol 214: 1201–1204Google Scholar
  22. Reinhardt D, Wagner J (1974) Beat-adrenolytic, antiarrhythmic and local anaesthetic effects of phenylephrine. Naunyn-Schmiedebergs Arch Pharmacol 284: 245–261Google Scholar
  23. Riegelman S, Loo JC, Rowland M (1968) Concept of a volume of distribution and possible errors in evaluation of this parameter. J Pharm Sci 57: 128–133Google Scholar
  24. Trendelenburg U, Muskus A, Flemming WW, Gomez Alonsa de la Sierra B (1962) Modification by reserpine of the action of sympathomimetic amines in spinal cats: a classification of sympathomimetic amines. J Pharmacol Exp Ther 138: 170–180Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • J. H. Hengstmann
    • 1
  • J. Goronzy
    • 1
  1. 1.Department of Internal MedicineUniversity of BonnBonnGermany

Personalised recommendations